Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Preeclampsia is a leading cause of maternal and neonatal death worldwide, yet effective strategies are lacking for prevention and treatment. A new paper published in the New England Journal of Medicine, explores the Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia.

Pre-eclampsia affects some pregnant women, usually during the second half of pregnancy (from around 20 weeks) or soon after their baby is delivered.
Pre-eclampsia affects some pregnant women, usually during the second half of pregnancy (from around 20 weeks) or soon after their baby is delivered.


Preeclampsia, a heterogeneous, multisystem disorder defined by the new onset of hypertension and proteinuria after 20 weeks of gestation, affects 2 to 5% of pregnancies worldwide. It is characterized by high blood pressure and a large amount of protein in the urine. Preeclampsia is associated with high risks of iatrogenic preterm delivery, intrauterine growth restriction, placental abruption, and perinatal mortality, along with maternal morbidity and mortality.

The cause of preeclampsia is incompletely understood, but the disorder is thought to be due to placental malperfusion resulting from abnormal remodeling of maternal spiral arteries. In preeclampsia, circulating maternal serum levels of soluble fms-like tyrosine kinase 1 (sFlt-1) are increased, and placental growth factor (PlGF) levels are decreased. An antagonist of PlGF and vascular endothelial growth factor, sFlt-1 causes vasoconstriction and endothelial damage that may lead to fetal growth restriction and preeclampsia. A high ratio of sFlt-1 to PlGF is associated with an increased risk of preeclampsia and may be a better predictor of risk than either biomarker alone.


There is a need for a reliable predictor of preeclampsia (particularly its absence) in the short term in women with suspected preeclampsia. Women with suggestive symptoms or signs are often hospitalized until preeclampsia and related adverse outcomes have been ruled out. Others who require hospitalization may be overlooked. Although no preventive or therapeutic strategy is yet available, with the exception of low-dose acetylsalicylic acid, which has a moderate preventive effect in high-risk pregnancies after the first trimester,  clinical experience suggests that early detection and monitoring are beneficial. 

Dr. Manu Vatish Senior Clinical Fellow in Obstetrics from the Nuffield Department of Obstetrics & Gynaecology collaborated on a new paper: Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. (New England Journal of Medicine) 

Read full paper here 

Read more about Improving the Prediction of Preeclampsia here

Read more about our Preeclampsia research here

Dr. Manu Vatish, Senior Clinical Fellow in Obstetrics 

Similar stories

New appointment at Bill & Melinda Gates Foundation

Congratulations to Manu Vatish, Professor of Obstetrics & Consultant Obstetrician who has been appointed as the new Deputy Director for Maternal and Child Health Discovery at the Bill & Melinda Gates Foundation.

Maternal fat metabolism in pregnancy and fetal abdominal growth influence child weight

A new study, led by researchers at the Nuffield Department of Women's & Reproductive Health, University of Oxford, in collaboration with the University of California, Berkeley, USA, published in The Lancet Diabetes & Endocrinology identifies, as early as the 5th month of pregnancy, patterns of fetal abdominal growth associated with maternal lipid metabolites that track newborn growth, adiposity and development into childhood.

New Professor of Obstetrics Title

Enormous well done to our new Professor Sally Collins - she was conferred the title of Professor of Obstetrics by the University's Medical Sciences Division Board.

INTERCOVID Study cited in the New Yorker

Fantastic news for our team who have been working on the INTERCOVID Study, which launched in April 2020. This week on 12th August 2022, the research findings cited in the New Yorker! This work was a combined effort from 43 institutions in 18 countries and involved more than two thousand pregnant women.

Women's Health Strategy for England Launched

The government has published the first ever Women's Health Strategy for England to tackle the gender health gap. Menopause, Endometriosis, Contraception and Fertility treatment are highlighted as some of the top issues women have asked for action on. The Nuffield Department of Women's & Reproductive Health welcome and fully support this bold and exciting strategy to help improve the health of millions of women in England.

Pregnancy is more likely with urine tests and timed intercourse

Dr Tatjana Gibbons leads study that suggests a woman's chance of conceiving is improved by using urine tests to detect the optimum time for intercourse, but further research is still needed to assess whether timed intercourse via any ovulation detection method creates a difference in live births and pregnancy rates.